Restylane® for the Treatment of Tear Trough Deformity

Inclusion criteria

• Female;
• Age of 18 years or greater;
• Indication for treatment of bilateral tear trough deformity;
• Symmetry of tear trough deformity at baseline;
• Subjects who understood and signed the Informed Consent Form (ICF) when entering the study, before performing any investigational procedure.

Exclusion criteria

• Prior (<1 year) or planning to undergo any surgery in the corporal area of interest for study;
• Any type of comorbidity or clinical condition that, at investigator's discretion, could interfere with study assessments;
• Diabetes mellitus type 1 or type 2;
• Autoimmune diseases, collagenosis, decompensated endocrine diseases or any disease that, at investigator's discretion, could interfere with study assessments;
• Using or have used within 3 months drugs such as corticosteroids, immunosuppressants or others collagen-production inhibitors;
• Initiated use of hormones or change in dose of hormonal replacement therapy within 3 months;
• Pregnant or breastfeeding, or wishes to get pregnant within the next 12 months, or refuses to use appropriate contraceptive method (in case of women of childbearing potential);
• Restylane® should not be used in any person who has hypersensitivity to any of the components of the product;
• Active skin inflammation or infection in or near the treatment area;
• Possessing any of the contraindications for use of Restylane®;
• Septal fat herniation;
• Severe elastosis (e.g., dermatochalasis);
• Use of Vitamin E, gingko biloba, Aspirin or non-steroidal anti-inflammatory drugs (NSAIDS) within 1 week of treatment.
• Use of tear trough injections in the last 12 months.
• Use of anterior midface injections in the last 12 months.